Home-based cardiac rehabilitation compared with centre-based rehabilitation and usual care: a systematic review and meta-analysis.

PubWeight™: 1.58‹?› | Rank: Top 4%

🔗 View Article (PMID 16316695)

Published in Int J Cardiol on November 28, 2005

Authors

Kate Jolly1, Rod S Taylor, Gregory Y H Lip, Andrew Stevens

Author Affiliations

1: Department of Public Health and Epidemiology, Public Health Building, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.

Articles citing this

Home based versus centre based cardiac rehabilitation: Cochrane systematic review and meta-analysis. BMJ (2010) 3.90

2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 3.63

Socioeconomic status and cardiovascular disease: risks and implications for care. Nat Rev Cardiol (2009) 2.25

Home versus day rehabilitation: a randomised controlled trial. Age Ageing (2008) 1.53

Home-based versus centre-based cardiac rehabilitation. Cochrane Database Syst Rev (2010) 1.38

Contribution of patient and physician factors to cardiac rehabilitation enrollment: a prospective multilevel study. Eur J Cardiovasc Prev Rehabil (2008) 1.21

Contribution of patient and physician factors to cardiac rehabilitation referral: a prospective multilevel study. Nat Clin Pract Cardiovasc Med (2008) 1.16

Adverse events among high-risk participants in a home-based walking study: a descriptive study. Int J Behav Nutr Phys Act (2007) 1.11

A mobile phone-based care model for outpatient cardiac rehabilitation: the care assessment platform (CAP). BMC Cardiovasc Disord (2010) 1.11

The effect of a self exercise program in cardiac rehabilitation for patients with coronary artery disease. Ann Rehabil Med (2011) 1.11

Drive time to cardiac rehabilitation: at what point does it affect utilization? Int J Health Geogr (2010) 0.98

Cardiac rehabilitation series: Canada. Prog Cardiovasc Dis (2013) 0.97

Geographic issues in cardiac rehabilitation utilization: a narrative review. Health Place (2010) 0.92

Home-based cardiac rehabilitation is an attractive alternative to no cardiac rehabilitation for elderly patients with coronary heart disease: results from a randomised clinical trial. BMJ Open (2012) 0.90

The effect of home-based cardiac rehabilitation program on self efficacy of patients referred to cardiac rehabilitation center. BMC Res Notes (2013) 0.86

"Flogging dead horses": evaluating when have clinical trials achieved sufficiency and stability? A case study in cardiac rehabilitation. Trials (2011) 0.85

"Prehabilitation" prior to CABG surgery improves physical functioning and depression. Int J Cardiol (2008) 0.85

The role of clinical and geographic factors in the use of hospital versus home-based cardiac rehabilitation. Int J Rehabil Res (2012) 0.82

International Charter on Cardiovascular Prevention and Rehabilitation: a call for action. J Cardiopulm Rehabil Prev (2013) 0.82

The challenge of obtaining information necessary for multi-criteria decision analysis implementation: the case of physiotherapy services in Canada. Cost Eff Resour Alloc (2013) 0.78

Feasibility and effectiveness of remote, telephone-based delivery of cardiac rehabilitation. Telemed J E Health (2013) 0.78

Poor use of cardiac rehabilitation among older adults: a self-regulatory model for tailored interventions. Heart Lung (2010) 0.78

Home-based versus centre-based cardiac rehabilitation: abridged Cochrane systematic review and meta-analysis. Open Heart (2016) 0.75

Behaviour change techniques in home-based cardiac rehabilitation: a systematic review. Br J Gen Pract (2016) 0.75

Self-Paced Walking within a Diverse Topographical Environment Elicits an Appropriate Training Stimulus for Cardiac Rehabilitation Patients. Rehabil Res Pract (2012) 0.75

Articles by these authors

Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J (2010) 16.39

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J (2012) 16.00

2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J (2012) 12.36

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail (2012) 10.38

A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest (2010) 10.29

Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet (2007) 10.10

Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97

2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. Europace (2012) 7.33

Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med (2012) 6.60

Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J (2006) 6.31

Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace (2010) 6.31

Acupuncture for 'frequent attenders' with medically unexplained symptoms: a randomised controlled trial (CACTUS study). Br J Gen Pract (2011) 5.95

Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ (2011) 5.84

Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.27

Association of a difference in systolic blood pressure between arms with vascular disease and mortality: a systematic review and meta-analysis. Lancet (2012) 5.14

Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev (2011) 4.72

Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂ score. Chest (2013) 4.71

Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med (2012) 4.69

Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med (2010) 4.15

Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 4.01

Home based versus centre based cardiac rehabilitation: Cochrane systematic review and meta-analysis. BMJ (2010) 3.90

Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet (2009) 3.83

Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J (2012) 3.66

Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol (2012) 3.49

Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation (2012) 3.47

Is atrial fibrillation an inflammatory disorder? Eur Heart J (2005) 3.33

Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. BMJ (2007) 3.30

The effectiveness of exercise interventions for people with Parkinson's disease: a systematic review and meta-analysis. Mov Disord (2008) 3.30

Spinal cord stimulation versus conventional medical management for neuropathic pain: a multicentre randomised controlled trial in patients with failed back surgery syndrome. Pain (2007) 3.27

Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol (2013) 3.13

Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol (2013) 3.06

Relation of nonsteroidal anti-inflammatory drugs to serious bleeding and thromboembolism risk in patients with atrial fibrillation receiving antithrombotic therapy: a nationwide cohort study. Ann Intern Med (2014) 2.91

Admissions processes for five year medical courses at English schools: review. BMJ (2006) 2.89

Mindfulness-based cognitive therapy to prevent relapse in recurrent depression. J Consult Clin Psychol (2008) 2.84

The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol (2008) 2.79

The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J (2003) 2.57

The difference in blood pressure readings between arms and survival: primary care cohort study. BMJ (2012) 2.56

Anxiety, depression, and prognosis after myocardial infarction: is there a causal association? J Am Coll Cardiol (2003) 2.54

How does mindfulness-based cognitive therapy work? Behav Res Ther (2010) 2.53

Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am J Cardiol (2005) 2.47

New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol (2012) 2.41

RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J (2011) 2.40

Role of microRNAs in cardiac remodelling: new insights and future perspectives. Int J Cardiol (2012) 2.32

Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost (2014) 2.29

Advances in heart rate variability signal analysis: joint position statement by the e-Cardiology ESC Working Group and the European Heart Rhythm Association co-endorsed by the Asia Pacific Heart Rhythm Society. Europace (2015) 2.26

An investigation into general practitioners associated with high patient mortality flagged up through the Shipman inquiry: retrospective analysis of routine data. BMJ (2004) 2.26

Virchow's triad revisited. South Med J (2004) 2.23

Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost (2011) 2.22

Bridging evidence-based practice and practice-based evidence in periprocedural anticoagulation. Circulation (2012) 2.20

Quality of life in patients with atrial fibrillation: a systematic review. Am J Med (2006) 2.17

Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J (2013) 2.17

Salt intake and Helicobacter pylori infection. J Hypertens (2004) 2.17

Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation (2012) 2.16

Endothelial progenitor cells in cardiovascular disorders. J Am Coll Cardiol (2007) 2.11

Reduced dietary salt for the prevention of cardiovascular disease. Cochrane Database Syst Rev (2014) 2.10

Ambulatory blood pressure monitoring in heart failure: a systematic review. Eur J Heart Fail (2005) 2.09

Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score? Circ Cardiovasc Interv (2012) 2.07

Indications for the use of diagnostic implantable and external ECG loop recorders. Europace (2009) 2.06

Prevalence of peripheral artery disease by abnormal ankle-brachial index in atrial fibrillation: implications for risk and therapy. J Am Coll Cardiol (2013) 2.05

Large-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-1 levels. Hum Mol Genet (2010) 2.05

Warfarin versus aspirin for prevention of cognitive decline in atrial fibrillation: randomized controlled trial (Birmingham Atrial Fibrillation Treatment of the Aged Study). Stroke (2014) 2.05

Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost (2011) 2.01

Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS One (2013) 1.97

Ischemic stroke in South Asians: a review of the epidemiology, pathophysiology, and ethnicity-related clinical features. Stroke (2009) 1.97

Psychological factors in heart failure: a review of the literature. Arch Intern Med (2002) 1.96

The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia (2002) 1.96

Inflammation in atrial fibrillation. J Am Coll Cardiol (2012) 1.95

Asymptomatic hypoxia in a young pregnant lady--unusual presentation of atrial septal defect. Int J Cardiol (2009) 1.92

Doctors record higher blood pressures than nurses: systematic review and meta-analysis. Br J Gen Pract (2014) 1.91

Outcome parameters for trials in atrial fibrillation: executive summary. Eur Heart J (2007) 1.90

Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ (2005) 1.90

Clinical service organisation for heart failure. Cochrane Database Syst Rev (2012) 1.90

Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol (2008) 1.89

Accuracy of diagnosing atrial fibrillation on electrocardiogram by primary care practitioners and interpretative diagnostic software: analysis of data from screening for atrial fibrillation in the elderly (SAFE) trial. BMJ (2007) 1.86

Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J (2006) 1.84

Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management. Chest (2009) 1.84

School-based violence prevention programs: systematic review of secondary prevention trials. Arch Pediatr Adolesc Med (2002) 1.83

The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. Eur Heart J (2012) 1.82

Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J (2014) 1.81

Nurse led interventions to improve control of blood pressure in people with hypertension: systematic review and meta-analysis. BMJ (2010) 1.80

Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. Eur Heart J (2009) 1.79

The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thromb Haemost (2012) 1.78

A 12-year follow-up study of patients with newly diagnosed lone atrial fibrillation: implications of arrhythmia progression on prognosis: the Belgrade Atrial Fibrillation study. Chest (2011) 1.77

Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol (2012) 1.76

Quality of life, resource consumption and costs of spinal cord stimulation versus conventional medical management in neuropathic pain patients with failed back surgery syndrome (PROCESS trial). Eur J Pain (2008) 1.76

Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis (2004) 1.76

Circulating endothelial cells. Biomarker of vascular disease. Thromb Haemost (2005) 1.73

Spinal cord stimulation versus reoperation for failed back surgery syndrome: a cost effectiveness and cost utility analysis based on a randomized, controlled trial. Neurosurgery (2007) 1.73

The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol (2013) 1.72

The effect of universal leukoreduction on postoperative infections and length of hospital stay in elective orthopedic and cardiac surgery. Transfusion (2004) 1.71

Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and -9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and -2. Thromb Res (2005) 1.71

Volume status and diuretic therapy in systolic heart failure and the detection of early abnormalities in renal and tubular function. J Am Coll Cardiol (2011) 1.70

Patients' understanding of anticoagulant therapy in a multiethnic population. J R Soc Med (2003) 1.69

Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation (2010) 1.68

Internet-based behavioral activation--treatment for postnatal depression (Netmums): a randomized controlled trial. J Affect Disord (2013) 1.68

Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol (2011) 1.67

Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes. Clin Sci (Lond) (2002) 1.67

'DNA' may not mean 'did not participate': a qualitative study of reasons for non-adherence at home- and centre-based cardiac rehabilitation. Fam Pract (2007) 1.66

Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. Circulation (2014) 1.65